Atlas Trials

Safety and Immunogenicity of Prime-boost Vaccination of SARS-CoV-2 in Patients With Cancer

Clinical trial NCT05273541 · UNKNOWN

Trial details

NCT number
NCT05273541
Sponsor
Beijing 302 Hospital
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Patients With CancerVaccine ReactionCOVID-19
Start date
2022-02-11
Primary completion
2022-12-30
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.